Skip to main
  1. Stocks
  2. CareDx
  3. Forecast
CDNA

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

CareDx is benefiting from unusually strong execution, with Q3'26 revenue of $139M (+39% Y/Y), Adj. EBITDA of $30M, 74% gross margins, and $250M of cash with no debt, while its core transplant volumes rose 21% Y/Y to nearly 61k. The bullish case is reinforced by the favorable CMS transplant LCD, which removed a major reimbursement overhang and preserved the HeartCare bundle, giving the company a clearer runway for higher volumes and ASPs across kidney, heart, and lung testing. Management also has credible growth vectors beyond transplant, including Naveris in oncology MRD, the planned AlloHeme launch in 2027, and expanded Epic integration, all supported by a strong competitive position and improving revenue cycle management.

Bears say

CareDx is exposed to a narrow revenue base, with financial results heavily reliant on AlloSure Kidney and AlloMap Heart, making the company vulnerable if reimbursement or utilization fails to scale as expected. Its growth strategy also depends on commercializing new transplant diagnostics, but those programs require substantial R&D, clinical validation, approvals, and years of development, while the underlying transplant testing market is evolving rapidly. Adoption risk remains high because clinicians and healthcare administrators may be slow to change historical practices due to liability and reimbursement concerns, limiting uptake of AlloSure Kidney, AlloMap Heart, and other solutions.

CareDx (CDNA) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

CareDx (CDNA) Analyst Forecast & Price Prediction

Get the latest CareDx (CDNA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CareDx (CDNA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 5 analysts, CareDx (CDNA) has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $67.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $67.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


CareDx (CDNA) Analyst Forecast & Price Prediction

Get the latest CareDx (CDNA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CareDx (CDNA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CDNA stock data and trends